tbuckley/cabot-search huggingface dataset:
Developmental-status-aware transcriptional decomposition establishes a cell state panorama of human cancers
Authors: Yikai Luo, Han Liang
Journal: Genome Medicine (2024)

Abstract Background Cancer cells evolve under unique functional adaptations that unlock transcriptional programs embedded in adult stem and progenitor-like cells for progression, metastasis, and therapeutic resistance. However, it remains challenging to quantify the stemness-aware cell state of a tumor based on its gene expression profile. Methods We develop a developmental-status-aware transcriptional decomposition strategy using single-cell RNA-sequencing-derived tissue-specific fetal and adult cell signatures as anchors. We apply our method to various biological contexts, including developing human organs, adult human tissues, experimentally induced differentiation cultures, and bulk human tumors, to benchmark its performance and to reveal novel biology of entangled developmental signaling in oncogenic processes. Results Our strategy successfully captures complex dynamics in developmental tissue bulks, reveals remarkable cellular heterogeneity in adult tissues, and resolves the ambiguity of cell identities in in vitro transformations. Applying it to large patient cohorts of bulk RNA-seq, we identify clinically relevant cell-of-origin patterns and observe that decomposed fetal cell signals significantly increase in tumors versus normal tissues and metastases versus primary tumors. Across cancer types, the inferred fetal-state strength outperforms published stemness indices in predicting patient survival and confers substantially improved predictive power for therapeutic responses. Conclusions Our study not only provides a general approach to quantifying developmental-status-aware cell states of bulk samples but also constructs an information-rich, biologically interpretable, cell-state panorama of human cancers, enabling diverse translational applications.
Tucidinostat plus pediatric-inspired chemotherapy for newly diagnosed adult ETP-ALL/LBL: a single-arm, phase 2 trial
Authors: Jieping Lin, Zicong Huang, Zihong Cai, Jia Li, Zhen Li, Chenhao Ding, Zhixiang Wang, Xiaofang Li, Xuan Zhou, Bailin He, Wenhao Zhong, Li Xuan, Qifa Liu, Yang Xu, Hongsheng Zhou
Journal: Journal of Hematology & Oncology (2024)

Early T-cell precursor lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) is a distinct subtype of T-ALL/LBL, characterized by a poor response to initial chemotherapy, a high relapse rate, and an inferior outcome. The treatment options for ETP-ALL/LBL are currently limited, and there are no reported clinical trials available for ETP-ALL/LBL. From June 2018 to June 2022, we conducted a single-arm, single-center, phase 2 trial (NCT03553238) in newly diagnosed ETP-ALL/LBL (age 14–55). Patients (N = 54) received pediatric-inspired chemotherapy plus tucidinostat, which was orally administered once daily at a dosage of 10 mg from induction to consolidation therapy. The primary endpoint was 3 year event-free survival (EFS). Secondary endpoints were overall survival (OS), relapse-free survival (RFS), complete remission rate and adverse events. The composite complete remission (CRc, complete response [CR] plus complete response with incomplete blood count recovery [CRi]) rate and MRD negativity after induction therapy was 91% (49 of 54 patients) and 65% (35 of 54 patients), respectively. The MRD negativity after consolidation was achieved in 87% patients (47 of 54 patients). With a median follow-up of 39.3 months (IQR, 20.6 to 60.0), the 3 year EFS rate was 67.7% (95% CI 56.2–81.7), the 3 year OS rate was 71.5% (95% CI 60.2–84.9) and the 3 year RFS rate was 67.5% (95% CI 55.9–81.6). The most common grade 3–4 adverse events were neutropenia (94%), anemia (85%), thrombocytopenia (76%), and infection (53%). Tucidinostat plus pediatric regimen is an effective and well-tolerated regimen for new diagnosed ETP-ALL/LBL, with high CRc and MRD negativity rates, as well as encouraging survival outcomes.
The Challenge of Treating Infections Caused by Metallo‐β‐Lactamase–Producing Gram-Negative Bacteria: A Narrative Review
Authors: Carmen Hidalgo-Tenorio, German Bou, Antonio Oliver, Montserrat Rodríguez-Aguirregabiria, Miguel Salavert, Luis Martínez-Martínez
Journal: Drugs (2024)

Gram-negative multidrug-resistant (MDR) bacteria, including Enterobacterales, Acinetobacter baumannii, and Pseudomonas aeruginosa, pose a significant challenge in clinical practice. Infections caused by metallo-β-lactamase (MBL)–producing Gram-negative organisms, in particular, require careful consideration due to their complexity and varied prevalence, given that the microbiological diagnosis of these pathogens is intricate and compounded by challenges in assessing the efficacy of anti-MBL antimicrobials. We discuss both established and new approaches in the treatment of MBL–producing Gram-negative infections, focusing on 3 strategies: colistin; the recently approved combination of aztreonam with avibactam (or with ceftazidime/avibactam); and cefiderocol. Despite its significant activity against various Gram-negative pathogens, the efficacy of colistin is limited by resistance mechanisms, while nephrotoxicity and acute renal injury call for careful dosing and monitoring in clinical practice. Aztreonam combined with avibactam (or with avibactam/ceftazidime if aztreonam plus avibactam is not available) exhibits potent activity against MBL–producing Gram-negative pathogens. Cefiderocol in monotherapy is effective against a wide range of multidrug-resistant organisms, including MBL producers, and favorable clinical outcomes have been observed in various clinical trials and case series. After examining scientific evidence in the management of infections caused by MBL–producing Gram-negative bacteria, we have developed a comprehensive clinical algorithm to guide therapeutic decision making. We recommend reserving colistin as a last-resort option for MDR Gram-negative infections. Cefiderocol and aztreonam/avibactam represent favorable options against MBL–producing pathogens. In the case of P. aeruginosa with MBL–producing enzymes and with difficult-to-treat resistance, cefiderocol is the preferred option. Further research is needed to optimize treatment strategies and minimize resistance.
Bempedoic acid suppresses diet-induced hepatic steatosis independently of ATP-citrate lyase
Authors: Joyce Y Liu, Ramya S Kuna, Laura V Pinheiro, Phuong T T Nguyen, Jaclyn E Welles, Jack M Drummond, Nivitha Murali, Prateek Sharma, Julianna G Supplee, Mia Shiue, Steven Zhao, Aimee T Farria, Avi Kumar, Mauren L Ruchhoeft, Christina Demetriadou, Daniel S Kantner, Adam Chatoff, Emily Megill, Paul M Titchenell, Nathaniel W Snyder, Christian M Metallo, Kathryn E Wellen
Journal: Cell Metabolism (2024)
Hexokinase 2 senses fructose in tumor-associated macrophages to promote colorectal cancer growth
Authors: Huiwen Yan, Zhi Wang, Da Teng, Xiaodong Chen, Zijing Zhu, Huan Chen, Wen Wang, Ziyuan Wei, Zhenzhen Wu, Qian Chai, Fei Zhang, Youwang Wang, Kaile Shu, Shaotang Li, Guizhi Shi, Mingzhao Zhu, Hai-Long Piao, Xian Shen, Pengcheng Bu
Journal: Cell Metabolism (2024)
A hierarchical hepatic de novo lipogenesis substrate supply network utilizing pyruvate, acetate, and ketones
Authors: Adam J Rauckhorst, Ryan D Sheldon, Daniel J Pape, Adnan Ahmed, Kelly C Falls-Hubert, Ronald A Merrill, Reid F Brown, Kshitij Deshmukh, Thomas A Vallim, Stanislaw Deja, Shawn C Burgess, Eric B Taylor
Journal: Cell Metabolism (2024)
Transcatheter Aortic Valve Replacement in Patients With Systolic Heart Failure and Moderate Aortic Stenosis
Authors: Nicolas M Van Mieghem, Sammy Elmariah, Ernest Spitzer, Philippe Pibarot, Tamim M Nazif, Jeroen J Bax, Rebecca T Hahn, Alexandra Popma, Ori Ben-Yehuda, Faouzi Kallel, Björn Redfors, Michael L Chuang, Maria C Alu, Wietze Lindeboom, Dhaval Kolte, Firas E Zahr, Susheel K Kodali, Justin A Strote, Renicus S Hermanides, David J Cohen, Jan G P Tijssen, Martin B Leon
Journal: Journal of the American College of Cardiology (2024)
Integrative single-cell multi-omics of CD19-CARpos and CARneg T cells suggest drivers of immunotherapy response in B cell neoplasias
Authors: Mercedes Guerrero-Murillo, Aina Rill-Hinarejos, Juan L Trincado, Alex Bataller, Valentín Ortiz-Maldonado, Daniel Benítez-Ribas, Marta Español-Rego, E Azucena González-Navarro, Nuria Martínez-Cibrián, Doménica Marchese, Lourdes Martín-Martín, Alejandro Martín García-Sancho, Susana Rives, Holger Heyn, Manel Juan, Álvaro Urbano-Ispizúa, Julio Delgado, Alberto Orfao, Elisabetta Mereu, Clara Bueno, Pablo Menendez
Journal: Cell Reports Medicine (2024)

The impact of phenotypic, clonal, and functional heterogeneity of chimeric antigen receptor (CAR)-T cells on clinical outcome remains understudied. Here, we integrate clonal kinetics with transcriptomic heterogeneity resolved by single-cell omics to interrogate cellular dynamics of non-transduced (CAR
Comprehensive analysis of Mycobacterium tuberculosis genomes reveals genetic variations in bacterial virulence
Authors: Wittawin Worakitchanon, Hideki Yanai, Pundharika Piboonsiri, Reiko Miyahara, Supalert Nedsuwan, Worarat Imsanguan, Boonchai Chaiyasirinroje, Waritta Sawaengdee, Sukanya Wattanapokayakit, Nuanjan Wichukchinda, Yosuke Omae, Prasit Palittapongarnpim, Katsushi Tokunaga, Surakameth Mahasirimongkol, Akihiro Fujimoto
Journal: Cell Host & Microbe (2024)
Bioadaptor implant versus contemporary drug-eluting stent in percutaneous coronary interventions in Sweden (INFINITY-SWEDEHEART): a single-blind, non-inferiority, registry-based, randomised controlled trial
Authors: David Erlinge, Jonas Andersson, Ole Fröbert, Mattias Törnerud, Mehmet Hamid, Thomas Kellerth, Per Grimfjärd, Oscar Winnberg, Juliane Jurga, Henrik Wagner, Sammy Zwackman, Martin Adielsson, Patrik Alström, Elli Masoe, Anders Ulvenstam, Jonas Millgård, Felix Böhm, Claes Held, Henrik Renlund, Jonas Oldgren, Pieter C Smits, Candace Elek, Andrea Abizaid, Stefan James
Journal: The Lancet (2024)
Metatranscriptomics-guided discovery and characterization of a polyphenol-metabolizing gut microbial enzyme
Authors: Minwoo Bae, Chi Le, Raaj S Mehta, Xueyang Dong, Lindsey M Pieper, Lorenzo Ramirez, Margaret Alexander, Sina Kiamehr, Peter J Turnbaugh, Curtis Huttenhower, Andrew T Chan, Emily P Balskus
Journal: Cell Host & Microbe (2024)
Standard-of-Care Medication Withdrawal in Patients With Obstructive Hypertrophic Cardiomyopathy Receiving Aficamten in FOREST-HCM
Authors: Ahmad Masri, Lubna Choudhury, Roberto Barriales-Villa, Perry Elliott, Martin S Maron, Michael E Nassif, Artur Oreziak, Anjali Tiku Owens, Sara Saberi, Albree Tower-Rader, Florian Rader, Pablo Garcia-Pavia, Iacopo Olivotto, Sherif F Nagueh, Andrew Wang, Stephen B Heitner, Daniel L Jacoby, Stuart Kupfer, Fady I Malik, Chiara Melloni, Lisa Meng, Jenny Wei, Mark V Sherrid, Theodore P Abraham
Journal: Journal of the American College of Cardiology (2024)

Standard-of-care (SoC) medications for the treatment of obstructive hypertrophic cardiomyopathy (oHCM) are recommended as first-line therapy despite the lack of evidence from controlled clinical trials and well known off-target side effects.
Multifaceted Hydrogel Scaffolds: Bridging the Gap between Biomedical Needs and Environmental Sustainability (Adv. Healthcare Mater. 27/2024)
Authors: Narsimha Mamidi, Fátima Franco De Silva, Alejandro Bedón Vacas, Javier Adonay Gutiérrez Gómez, Naomi Yael Montes Goo, Daniela Ruiz Mendoza, Rui L. Reis, Subhas C. Kundu
Journal: Advanced Healthcare Materials (2024)
Improvement of Therapeutic Effect via Inducing Non‐Apoptotic Cell Death Using mRNA‐Protection Nanocage (Adv. Healthcare Mater. 27/2024)
Authors: Seoyoung Kim, Seongchan Kim, Sojin Kim, Nan‐Ee Lee, Soo‐Hwan Lee, Hyunkyung Kim, Hyojin Lee
Journal: Advanced Healthcare Materials (2024)
A 3D Bioprinted Cortical Organoid Platform for Modeling Human Brain Development (Adv. Healthcare Mater. 27/2024)
Authors: Melissa A. Cadena, Anson Sing, Kylie Taylor, Linqi Jin, Liqun Ning, Mehdi Salar Amoli, Yamini Singh, Samantha N. Lanjewar, Martin L. Tomov, Vahid Serpooshan, Steven A. Sloan
Journal: Advanced Healthcare Materials (2024)
Maturation of Human iPSC‐Derived Cardiac Microfiber with Electrical Stimulation Device (Adv. Healthcare Mater. 27/2024)
Authors: Akari Masuda, Yuta Kurashina, Hidenori Tani, Yusuke Soma, Jumpei Muramatsu, Shun Itai, Shugo Tohyama, Hiroaki Onoe
Journal: Advanced Healthcare Materials (2024)
Bioconjugated Antibody‐Trojan Immune Converter Enhance Cancer Immunotherapy with Minimized Toxicity by Programmed Two‐Step Immunomodulation of Myeloid Cells (Adv. Healthcare Mater. 27/2024)
Authors: Soyoung Park, Seung Mo Jin, Suhyeon Kim, Ju Hee Cho, JungHyub Hong, Yong‐Soo Bae, Yong Taik Lim
Journal: Advanced Healthcare Materials (2024)
Microenvironment‐Responsive Targeted Nanomedicine for a Collaborative Integration of Tumor Theranostics and Bone Defect Repair (Adv. Healthcare Mater. 27/2024)
Authors: Wenxuan Wang, Weiwei Kang, Xin Zhang, Xiaochun Zheng, Yarong Jin, Zhuo Ma, Yuhang Wang, Rong Dai, Xun Ma, Ziliang Zheng, Ruiping Zhang
Journal: Advanced Healthcare Materials (2024)
Correspondence to The Risk of Lung Cancer in Rheumatoid Arthritis and Rheumatoid Arthritis‐Associated Interstitial Lung Disease
Authors: Tsai Yi Hung, Chen Dong, Brian Shiian Chen, James Cheng Chung Wei
Journal: Arthritis & Rheumatology (2024)

Disclosure Form Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Clinical Characteristics of Anti‐Synthetase Syndrome: Analysis from the <scp>CLASS</scp> project
Authors: Sara Faghihi‐Kashani, Akira Yoshida, Francisca Bozan, Giovanni Zanframundo, Davide Rozza, Aravinthan Loganathan, Eduardo Dourado, Gianluca Sambataro, Iazsmin Bauer Ventura, Sangmee Sharon Bae, Darosa Lim, Daphne Rivero Gallegos, Yasuhiko Yamano, Albert Selva‐O'Callaghan, Andrew L. Mammen, Carlo A. Scirè, Carlomaurizio Montecucco, Chester V. Oddis, David Fiorentino, Francesco Bonella, Frederick W. Miller, Ingrid E. Lundberg, Jens Schmidt, Jorge Rojas‐Serrano, Marie Hudson, Masataka Kuwana, Miguel Angel González‐Gay, Neil McHugh, Tamera J. Corte, Tracy Jennifer Doyle, Victoria P. Werth, Latika Gupta, Diana Isabel Perez Roman, Lorenzo M. Bianchessi, Phani Kumar Devarasetti, Samuel Katsuyuki Shinjo, Fabrizio Luppi, Ilaria Cavazzana, Siamak Moghadam‐Kia, Marco Fornaro, Elizabeth R. Volkmann, Matteo Piga, Jesus Loarce‐Martos, Giacomo De Luca, Johannes Knitza, Veronica Wolff‐Cecchi, Marco Sebastiani, Adam Schiffenbauer, Lisa G. Rider, Raquel Campanilho‐Marques, Lucian Marts, Elena Bravi, Harsha Gunawardena, Rohit Aggarwal, Lorenzo Cavagna
Journal: Arthritis & Rheumatology (2024)

Objective Anti‐synthetase syndrome (ASSD) is a rare systemic autoimmune rheumatic disease (SARD) with significant heterogeneity and no shared classification criteria. We aimed to identify clinical and serological features associated with ASSD that may be suitable for inclusion in the data‐driven classification criteria for ASSD. Methods We utilized a large, international, multi‐center “ Classification Criteria for Anti‐synthetase Syndrome ” (CLASS) project database, which includes both ASSD patients and controls with mimicking conditions, namely SARDs and/or interstitial lung disease (ILD). The local diagnoses of ASSD and controls were confirmed by project team members. We employed univariable logistic regression and multivariable Ridge regression to evaluate clinical and serological features associated with an ASSD diagnosis in a randomly selected subset of the cohort. Results Our analysis included 948 ASSD cases and 1077 controls. Joint, muscle, lung, skin, and cardiac involvement were more prevalent in ASSD than in controls. Specific variables associated with ASSD included arthritis, diffuse myalgia, muscle weakness, muscle enzyme elevation, ILD, mechanic's hands, secondary pulmonary hypertension due to ILD, Raynaud phenomenon, and unexplained fever. In terms of serological variables, Jo‐1 and non‐Jo‐1 anti‐synthetase autoantibodies, antinuclear antibodies with cytoplasmic pattern, and anti‐Ro52 autoantibodies were associated with ASSD. In contrast, isolated arthralgia, dysphagia, electromyography/MRI/muscle biopsy findings suggestive of myopathy, inflammatory rashes, myocarditis, and pulmonary arterial hypertension did not differentiate between ASSD and controls or were inversely associated with ASSD. Conclusion We identified key clinical and serological variables associated with ASSD, which will help clinicians and offer insights into the development of data‐driven classification criteria for ASSD. image
Proteomic biomarkers and pathway analysis for progression to heart failure in three epidemiological representative cohorts
Authors: Anna Dieden, Nicolas Girerd, Filip Ottosson, John Molvin, Manan Pareek, Olle Melander, Erasmus Bachus, Lennart Råstam, Ulf Lindblad, Bledar Daka, Margrét Leósdóttir, Peter M. Nilsson, Michael H. Olsen, Andrew L. Clark, John G.F. Cleland, Christian Delles, Arantxa González, Zohra Lamiral, Kevin Duarte, Patrick Rossignol, Faiez Zannad, Petri Gudmundsson, Amra Jujić, Martin Magnusson
Journal: European Journal of Heart Failure (2024)
PRISM: Patient Records Interpretation for Semantic clinical trial Matching system using large language models
Authors: Shashi Gupta, Aditya Basu, Mauro Nievas, Jerrin Thomas, Nathan Wolfrath, Adhitya Ramamurthi, Bradley Taylor, Anai N. Kothari, Regina Schwind, Therica M. Miller, Sorena Nadaf-Rahrov, Yanshan Wang, Hrituraj Singh
Journal: npj Digital Medicine (2024)

Clinical trial matching is the task of identifying trials for which patients may be eligible. Typically, this task is labor-intensive and requires detailed verification of patient electronic health records (EHRs) against the stringent inclusion and exclusion criteria of clinical trials. This process also results in many patients missing out on potential therapeutic options. Recent advancements in Large Language Models (LLMs) have made automating patient-trial matching possible, as shown in multiple concurrent research studies. However, the current approaches are confined to constrained, often synthetic, datasets that do not adequately mirror the complexities encountered in real-world medical data. In this study, we present an end-to-end large-scale empirical evaluation of a clinical trial matching system and validate it using real-world EHRs. We perform comprehensive experiments with proprietary LLMs and our custom fine-tuned model called OncoLLM and show that OncoLLM outperforms GPT-3.5 and matches the performance of qualified medical doctors for clinical trial matching.
Mixed Cardiogenic Shock: A Proposal for Standardized Classification, a Hemodynamic Definition, and Framework for Management
Authors: Sean van Diepen, Janine Pöss, Janek M. Senaratne, Ann Gage, David A. Morrow
Journal: Circulation (2024)

The classification of cardiogenic shock (CS) has evolved from a singular cold-and wet-hemodynamic profile. Data from registries and clinical trials have contributed to a broader recognition that although all patients with CS have insufficient cardiac output leading to end organ hypoperfusion, there is considerable variability in CS acuity, underlying etiologies, volume status, and systemic vascular resistance. Mixed CS can be broadly categorized as CS with at least 1 additional shock state . Mixed CS states are now the second leading cause of shock in contemporary coronary intensive care units, but there is little high-quality evidence to guide routine care, and there are no standardized classification frameworks or well-established hemodynamic definitions. This primer summarizes the current epidemiology and proposes a classification framework and invasive hemodynamic parameters to guide categorization that could be applied to help better phenotype patients captured in registries and trials, as well as guide management of mixed CS states.
Prevalence of Coronary Atherosclerosis in Female Masters Endurance Athletes
Authors: Efstathios Papatheodorou, Vincent L. Aengevaeren, Thijs M.H. Eijsvogels, Khaled AlFakih, Rebecca Kathryn Hughes, Ahmed Merghani, Christine K. Kissel, Saad Fyyaz, Athanasios Bakalakos, Mathew G. Wilson, Damini Dey, Gherardo Finocchiaro, Gemma Parry-Williams, Camilla Torlasco, Michael Papadakis, James C. Moon, Sanjay Sharma
Journal: Circulation (2024)
Clinically Relevant and Precisely Printable Live Adipose Tissue–Based Bio‐Ink for Volumetric Soft Tissue Reconstruction
Authors: Wonwoo Jeong, Jeonghyun Son, Jeonghan Choi, Jonghyeuk Han, Seunggyu Jeon, Min Kyeong Kim, Won Ha, Hyun‐Wook Kang
Journal: Advanced Healthcare Materials (2024)

Abstract Autologous fat is widely used in soft tissue reconstruction; however, significant volume reduction owing to necrosis and degradation of the transplanted adipose tissue (AT) remains a major challenge. To address this issue, a novel live AT micro‐fragment–based bio‐ink (ATmf bio‐ink) compatible with precision 3D printing, is developed. Live AT micro‐fragments of ≈280 µm in size are prepared using a custom tissue micronizer and they are incorporated into a fibrinogen/gelatin mixture to create the ATmf bio‐ink. AT micro‐fragments exhibit high viability and preserve the heterogeneous cell population and extracellular matrix of the native AT. The developed bio‐ink enables precise micropatterning and provides an excellent adipo‐inductive microenvironment. AT grafts produced by co‐printing the bio‐ink with polycaprolactone demonstrate a 500% improvement in volume retention and a 300% increase in blood vessel infiltration in vivo compared with conventional microfat grafts. In vivo engraftment of AT grafts is further enhanced by using a stem cell–laden ATmf bio‐ink. Last, it is successfully demonstrated that the bio‐ink is enabled for the creation of clinically relevant and patient‐specific AT grafts for patients undergoing partial mastectomy. This novel ATmf bio‐ink for volumetric soft tissue reconstruction offers a pioneering solution for addressing the limitations of existing clinical techniques.
Brief report: Ivonescimab combined with etoposide plus carboplatin as first-line treatment for extensive-stage small-cell lung cancer: results of a phase Ib clinical trial
Authors: Zhiwei Chen, Lin Wu, Qiming Wang, Yan Yu, Xianling Liu, Rui Ma, Tao Li, Yan Li, Xia Song, Lin Li, Wei Zhao, Qiaoyun Wang, Xiao Xu, Shun Lu
Journal: Journal of Thoracic Oncology (2024)
Author Correction: Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes
Authors: Muthiah Vaduganathan, Gerasimos Filippatos, Brian L. Claggett, Akshay S. Desai, Pardeep S. Jhund, Alasdair Henderson, Meike Brinker, Peter Kolkhof, Patrick Schloemer, James Lay-Flurrie, Prabhakar Viswanathan, Carolyn S. P. Lam, Michele Senni, Sanjiv J. Shah, Adriaan A. Voors, Faiez Zannad, Peter Rossing, Luis M. Ruilope, Stefan D. Anker, Bertram Pitt, Rajiv Agarwal, John J. V. McMurray, Scott D. Solomon
Journal: Nature Medicine (2024)
<scp>STING</scp>‐dependent induction of neutrophilic asthma exacerbation in response to house dust mite
Authors: Yasmine Messaoud‐Nacer, Elodie Culerier, Stéphanie Rose, Isabelle Maillet, Rania Boussad, Chloé Veront, Florence Savigny, Bernard Malissen, Urszula Radzikowska, Milena Sokolowska, Gabriel V. L. da Silva, Michael R. Edwards, David J. Jackson, Sebastian L. Johnston, Bernhard Ryffel, Valerie F. Quesniaux, Dieudonnée Togbe
Journal: Allergy (2024)

Severe refractory, neutrophilic asthma remains an unsolved clinical problem. STING agonists induce a neutrophilic response in the airways, suggesting that STING activation may contribute to the triggering of neutrophilic exacerbations. We aim to determine whether STING-induced neutrophilic lung inflammation mimics severe asthma.